EP1718669A4 - Identification de nouveaux epitopes ige - Google Patents

Identification de nouveaux epitopes ige

Info

Publication number: EP1718669A4
Authority: EP; European Patent Office
Prior art keywords: identification; ige epitopes; novel ige; novel; epitopes
Prior art date: 2004-02-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP04779424A

Other languages

German (de)

English (en)

Other versions

EP1718669A1 (fr

Inventor

Sanjaya Singh

Danyang Huang

Sek Chung Michael Fung

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tanox Inc

Original Assignee

Tanox Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-02

Filing date

2004-07-29

Publication date

2007-10-10

2004-02-02 Priority claimed from PCT/US2004/002894 external-priority patent/WO2004070011A2/fr

2004-07-29 Application filed by Tanox Inc filed Critical Tanox Inc

2006-11-08 Publication of EP1718669A1 publication Critical patent/EP1718669A1/fr

2007-10-10 Publication of EP1718669A4 publication Critical patent/EP1718669A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Dermatology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Rheumatology (AREA)
Otolaryngology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

EP04779424A 2004-02-02 2004-07-29 Identification de nouveaux epitopes ige Withdrawn EP1718669A4 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/US2004/002894 WO2004070011A2 (fr)	2003-02-01	2004-02-02	Anticorps ige anti-humains a affinite elevee
PCT/US2004/002892 WO2004070010A2 (fr)	2003-02-01	2004-02-02	Procede destine a produire des anticorps a affinite elevee
PCT/US2004/024360 WO2005075504A1 (fr)	2004-02-02	2004-07-29	Identification de nouveaux epitopes ige

Publications (2)

Publication Number	Publication Date
EP1718669A1 EP1718669A1 (fr)	2006-11-08
EP1718669A4 true EP1718669A4 (fr)	2007-10-10

Family

ID=34841291

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP04779424A Withdrawn EP1718669A4 (fr)	2004-02-02	2004-07-29	Identification de nouveaux epitopes ige

Country Status (8)

Country	Link
EP (1)	EP1718669A4 (fr)
JP (1)	JP2008507474A (fr)
KR (4)	KR20070008578A (fr)
CN (1)	CN102702359A (fr)
AU (2)	AU2004315197B2 (fr)
CA (1)	CA2552999A1 (fr)
SG (2)	SG183683A1 (fr)
WO (1)	WO2005075504A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008019131A2 (fr) *	2006-08-04	2008-02-14	The Trustees Of The University Of Pennsylvania	PROCÉDÉS ET COMPOSITIONS DE TRAITEMENT DE MALADIES MÉDIÉES PAR l'IGE
US7833527B2 (en) *	2006-10-02	2010-11-16	Amgen Inc.	Methods of treating psoriasis using IL-17 Receptor A antibodies
AR065368A1 (es)	2007-02-15	2009-06-03	Astrazeneca Ab	Anticuerpos para moleculas de ige
KR20090114397A (ko) *	2007-02-15	2009-11-03	아스트라제네카 아베	Ｉｇｅ 분자에 대한 결합 멤버
EP2012122A1 (fr) *	2007-07-06	2009-01-07	Medigene AG	Protéines structurelles de parvovirus muté
AU2008339980A1 (en) *	2007-12-21	2009-07-02	Glaxosmithkline Biologicals S.A.	Vaccines for malaria
EP2865389A1 (fr)	2008-12-09	2015-04-29	Pfizer Vaccines LLC	Vaccin peptidique IgE CH3
CA2800774A1 (fr)	2010-06-07	2011-12-15	Pfizer Vaccines Llc	Vaccin peptidique ige ch3
CA3049967C (fr) *	2017-01-06	2024-10-01	Univ California	Anticorps anti-ige therapeutiques et methodes et compositions associees
CA3094749A1 (fr) *	2018-03-26	2019-10-03	Novartis Ag	Procedes de traitement de l'urticaire chronique spontanee a l'aide de ligelizumab
CA3220757A1 (fr)	2021-06-14	2022-12-22	Novartis Ag	Formulation pharmaceutique contenant des anticorps anti-ige

Citations (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0263655A2 (fr) *	1986-10-03	1988-04-13	Dainippon Pharmaceutical Co., Ltd.	Peptides à activité antiallergique
EP0957111A2 (fr) *	1998-04-09	1999-11-17	Idexx Laboratories, Inc.	Protéines de liaison spécifiques pour le traitement des allergies canines
WO2000023477A2 (fr) *	1998-10-20	2000-04-27	University Of Sheffield	Variants d'immunoglobuline
WO2000050461A1 (fr) *	1999-02-25	2000-08-31	Smithkline Beecham Biologicals S.A.	Epitopes ou mimotopes derives des domaines c-epsilon-3 ou c-epsilon-4 des ige, leurs antagonistes et leur utilisation therapeutique
WO2000074716A2 (fr) *	1999-06-08	2000-12-14	Smithkline Beecham Biologicals S.A.	Vaccin
WO2002016409A2 (fr) *	2000-08-22	2002-02-28	Glaxosmithkline Biologicals S.A.	Nouveaux composes et procede
EP1195161A2 (fr) *	2000-08-30	2002-04-10	Pfizer Products Inc.	Anti-IgE vaccins
WO2002034288A2 (fr) *	2000-10-27	2002-05-02	Smithkline Beecham Biologicals S.A.	Vaccin
EP1262491A2 (fr) *	2001-05-22	2002-12-04	Pfizer Products Inc.	Vaccines d'IgE non-anaphylactogènes
WO2003092714A2 (fr) *	2002-04-30	2003-11-13	Glaxosmithkline Biologicals S.A.	Vaccin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
PT589840E (pt) *	1992-09-24	2004-08-31	Tanox Biosystems Inc	Anticorpos monoclonais reformulados contra um isotipo de imunoglobulina
US6172213B1 (en) *	1997-07-02	2001-01-09	Genentech, Inc.	Anti-IgE antibodies and method of improving polypeptides
US7393529B2 (en) *	1998-04-09	2008-07-01	Idexx Laboratories, Inc.	Methods and compositions for inhibiting binding of IgE to a high affinity receptor
TWI227241B (en) *	1998-06-20	2005-02-01	United Biomedical Inc	IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
SI2407485T1 (sl) *	2003-02-01	2016-09-30	Tanox, Inc.	Visoko afinitetna anti-humana protitelesa IgE

2004
- 2004-07-29 CN CN2011103434066A patent/CN102702359A/zh active Pending
- 2004-07-29 JP JP2006551035A patent/JP2008507474A/ja active Pending
- 2004-07-29 SG SG2012057212A patent/SG183683A1/en unknown
- 2004-07-29 SG SG200900706-3A patent/SG149892A1/en unknown
- 2004-07-29 KR KR1020067017609A patent/KR20070008578A/ko not_active Withdrawn
- 2004-07-29 KR KR1020147000238A patent/KR101581659B1/ko not_active Expired - Lifetime
- 2004-07-29 CA CA002552999A patent/CA2552999A1/fr not_active Abandoned
- 2004-07-29 KR KR1020127009917A patent/KR101365375B1/ko not_active Expired - Lifetime
- 2004-07-29 EP EP04779424A patent/EP1718669A4/fr not_active Withdrawn
- 2004-07-29 KR KR1020137018993A patent/KR101562114B1/ko not_active Expired - Lifetime
- 2004-07-29 AU AU2004315197A patent/AU2004315197B2/en not_active Expired
- 2004-07-29 WO PCT/US2004/024360 patent/WO2005075504A1/fr not_active Ceased
2009
- 2009-06-16 AU AU2009202408A patent/AU2009202408A1/en not_active Abandoned

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0263655A2 (fr) *	1986-10-03	1988-04-13	Dainippon Pharmaceutical Co., Ltd.	Peptides à activité antiallergique
EP0957111A2 (fr) *	1998-04-09	1999-11-17	Idexx Laboratories, Inc.	Protéines de liaison spécifiques pour le traitement des allergies canines
WO2000023477A2 (fr) *	1998-10-20	2000-04-27	University Of Sheffield	Variants d'immunoglobuline
WO2000050461A1 (fr) *	1999-02-25	2000-08-31	Smithkline Beecham Biologicals S.A.	Epitopes ou mimotopes derives des domaines c-epsilon-3 ou c-epsilon-4 des ige, leurs antagonistes et leur utilisation therapeutique
WO2000074716A2 (fr) *	1999-06-08	2000-12-14	Smithkline Beecham Biologicals S.A.	Vaccin
WO2002016409A2 (fr) *	2000-08-22	2002-02-28	Glaxosmithkline Biologicals S.A.	Nouveaux composes et procede
EP1195161A2 (fr) *	2000-08-30	2002-04-10	Pfizer Products Inc.	Anti-IgE vaccins
WO2002034288A2 (fr) *	2000-10-27	2002-05-02	Smithkline Beecham Biologicals S.A.	Vaccin
EP1262491A2 (fr) *	2001-05-22	2002-12-04	Pfizer Products Inc.	Vaccines d'IgE non-anaphylactogènes
WO2003092714A2 (fr) *	2002-04-30	2003-11-13	Glaxosmithkline Biologicals S.A.	Vaccin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHANG T W ET AL: "MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN IGE-PRODUCING B CELLS A POTENTIAL THERAPEUTIC FOR IGE-MEDIATED ALLERGIC DISEASES", BIO-TECHNOLOGY (NEW YORK), vol. 8, no. 2, 1990, pages 122 - 126, XP009084134, ISSN: 0733-222X *
MACGLASHAN D W ET AL: "DOWN-REGULATION OF FCEPSILONRI EXPRESSION ON HUMAN BASOPHILS DURINGIN VIVO TREATMENT OF ATOPIC PATIENTS WITH ANTI-IGE ANTIBODY", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 158, 1997, pages 1438 - 1445, XP002930932, ISSN: 0022-1767 *
See also references of WO2005075504A1 *

Also Published As

Publication number	Publication date
JP2008507474A (ja)	2008-03-13
AU2004315197A1 (en)	2005-08-18
SG149892A1 (en)	2009-02-27
CA2552999A1 (fr)	2005-08-18
KR101581659B1 (ko)	2015-12-31
EP1718669A1 (fr)	2006-11-08
AU2009202408A1 (en)	2009-07-09
SG183683A1 (en)	2012-09-27
AU2004315197B2 (en)	2009-06-04
KR20140021058A (ko)	2014-02-19
KR101562114B1 (ko)	2015-11-20
WO2005075504A1 (fr)	2005-08-18
CN102702359A (zh)	2012-10-03
KR20130088198A (ko)	2013-08-07
KR20120056297A (ko)	2012-06-01
KR101365375B1 (ko)	2014-02-19
KR20070008578A (ko)	2007-01-17

Publication	Publication Date	Title
IL176940A0 (en)	2006-12-10	IDENTIFICATION OF NOVEL IgE EPITOPES
GB0412973D0 (en)	2004-07-14	Identification of antibody producing cells
ZA200609595B (en)	2008-06-25	Novel CIS-Imidazolines
IL179730A0 (en)	2007-05-15	Novel cis-imidazolines
IL211491A0 (en)	2011-05-31	4-(benzimidazolylmethylamino)-benzamidines
EP1778618A4 (fr)	2008-07-16	Synthese de triethylenetetramines
EP1756092A4 (fr)	2009-12-02	Inhibiteurs novateurs de protéines rho-kinases
TWI372750B (en)	2012-09-21	Novel hydroxy-6-heteroarylphenanthridines
EP1869192A4 (fr)	2010-10-20	Rearrangement de l'infrastructure d'anticorps
GB0426160D0 (en)	2004-12-29	Production of proteins
IL179811A0 (en)	2007-05-15	Identification of tumors
EP1965341A4 (fr)	2010-04-28	Carte permettant une authentification
EP1718669A4 (fr)	2007-10-10	Identification de nouveaux epitopes ige
EP1711484A4 (fr)	2007-06-20	Synthese de cyanoimino-benzoimidazoles
IL183106A0 (en)	2007-09-20	Production of proteins
GB0414026D0 (en)	2004-07-28	Novel uses
AU158223S (en)	2005-08-01	Wristwatch
ZA200610303B (en)	2010-05-26	Novel cis-imidazolines
IL178184A0 (en)	2006-12-31	Synthesis of pyrrole-2-carbonitriles
GB0505985D0 (en)	2005-04-27	Nail aid
GB0408865D0 (en)	2004-05-26	Novel benzoxazocines
ZA200606635B (en)	2008-05-28	Novel isoamido-substituted hydroxy-6-phenylphenanthridines
GB0424519D0 (en)	2004-12-08	Identification of micro-organisms
GB0413479D0 (en)	2004-07-21	Novel antibodies
ZA200508325B (en)	2008-05-28	Manufacture of kerbstones

Legal Events

Date	Code	Title	Description
2006-10-06	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2006-11-08	17P	Request for examination filed	Effective date: 20060824
2006-11-08	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
2006-11-08	AX	Request for extension of the european patent	Extension state: AL HR LT LV MK
2007-10-10	A4	Supplementary search report drawn up and despatched	Effective date: 20070912
2009-05-06	17Q	First examination report despatched	Effective date: 20090407
2013-11-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2013-12-04	18D	Application deemed to be withdrawn	Effective date: 20130625